Stock Yards Bank & Trust Co. Sells 5,409 Shares of CVS Health Corporation (NYSE:CVS)

Stock Yards Bank & Trust Co. trimmed its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 17.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,239 shares of the pharmacy operator's stock after selling 5,409 shares during the period. Stock Yards Bank & Trust Co.'s holdings in CVS Health were worth $1,778,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Norges Bank purchased a new stake in CVS Health in the 4th quarter worth about $839,574,000. Capital World Investors lifted its stake in CVS Health by 26.6% in the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock worth $2,739,927,000 after acquiring an additional 12,819,148 shares in the last quarter. Davis Selected Advisers lifted its stake in CVS Health by 2,998.1% in the 4th quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock worth $511,115,000 after acquiring an additional 11,018,438 shares in the last quarter. Dodge & Cox lifted its stake in CVS Health by 11.2% in the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock worth $3,147,054,000 after acquiring an additional 7,075,209 shares in the last quarter. Finally, Pzena Investment Management LLC lifted its stake in CVS Health by 49.3% in the 4th quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after acquiring an additional 6,475,271 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Up 0.2%

Shares of NYSE CVS traded up $0.12 during mid-day trading on Wednesday, reaching $67.21. 3,185,842 shares of the company traded hands, compared to its average volume of 10,927,995. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. The stock has a market cap of $85.02 billion, a PE ratio of 16.05, a price-to-earnings-growth ratio of 0.97 and a beta of 0.56. The company's fifty day moving average is $65.09 and its two-hundred day moving average is $60.25. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The company's revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.31 EPS. On average, analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is currently 63.48%.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of the stock in a transaction on Thursday, June 5th. The shares were purchased at an average price of $63.70 per share, with a total value of $100,009.00. Following the acquisition, the director now directly owns 12,007 shares of the company's stock, valued at $764,845.90. This represents a 15.04% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.22% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CVS shares. UBS Group increased their price objective on CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research note on Friday, May 2nd. Royal Bank Of Canada raised their price target on CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a research note on Monday, May 5th. JPMorgan Chase & Co. raised their price target on CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 18th. Barclays set a $79.00 price target on CVS Health and gave the stock an "overweight" rating in a research note on Monday, June 2nd. Finally, Cowen reaffirmed a "buy" rating on shares of CVS Health in a research note on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $74.75.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.